Advanced in Hemolytic Crisis

Aldo L. Renault

Pau, FR 
Advanced in Hemolytic Crisis
Pau, FR 
OverviewLocationsClinical Research

Overview

Aldo Renault practices in Pau, France. Mr. Renault is rated as an Advanced expert by MediFind in the treatment of Hemolytic Crisis. His top areas of expertise are Hemolytic Crisis, Bilirubin Encephalopathy, Small Cell Lung Cancer (SCLC), and Lung Cancer.

His clinical research consists of co-authoring 14 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Hemolytic Crisis.

Gender
Male

Locations

Pau, 64000, France
Other Locations
Creteil, France
194 Avenue Rubillard, Le Mans, 72037, France
Clermont-ferrand, France
Fontainebleau, France
26, Avenue Du Dr Arnold Netter, Paris, 75012, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase II, Multi-centre Study, to Evaluate the Efficacy and Safety of Osimertinib Treatment for Patients with EGFR-mutated Non-small Cell Lung Cancer (NSCLC) with Brain or Leptomeningeal Metastases
A Phase II, Multi-centre Study, to Evaluate the Efficacy and Safety of Osimertinib Treatment for Patients with EGFR-mutated Non-small Cell Lung Cancer (NSCLC) with Brain or Leptomeningeal Metastases
Enrollment Status: Completed
Publish Date: February 03, 2025
Intervention Type: Drug
Study Drug: Osimertinib
Study Phase: Phase 2
Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: SAFIR02_Lung - Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Non-small Cell Lung Cancer
Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: SAFIR02_Lung - Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Non-small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: January 10, 2024
Intervention Type: Drug
Study Drugs: AZD2014, AZD4547, AZD5363, AZD8931, Selumetinib, Vandetanib, Standard Maintenance, Pemetrexed, Durvalumab, Savolitinib, Olaparib
Study Phase: Phase 2
View 1 Less Clinical Trial

14 Total Publications

Real-World Outcomes of Pralsetinib in RET Fusion-Positive NSCLC.
Real-World Outcomes of Pralsetinib in RET Fusion-Positive NSCLC.
Journal: JTO clinical and research reports
Published: July 05, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Renault's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile